The present invention is based on the discovery of an association between the SNP genotype at the rs12979860 locus in the IL28B gene promoter and the probability of achieving a SVR in HC V-infected patients that are given a triple therapy treatment that contains peginterferon alfa-2a, ribavirin, and a HCV NS5B polymerase inhibitor.
申请公布号
WO2012130862(A1)
申请公布日期
2012.10.04
申请号
WO2012EP55450
申请日期
2012.03.28
申请人
F. HOFFMANN-LA ROCHE AG;IGLESIAS, VICTOR;IPE, DAVID;THOMMES, JAMES;ZHU, YONGHONG
